At a glance
ClinicalIndex Comparison RecordPhase 3Active· 603 enrolled
Drug / intervention
Sacituzumab Govitecan-hziy (SG) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
In Brief
A Phase 3 clinical trial evaluating Sacituzumab Govitecan-hziy (SG) and Docetaxel for Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 603 participants across 227 sites in 20 countries.
Detailed Summary
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Austria, Belgium, Brazil, Canada, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3Active
202220232024202520262027
First PostedOct 2021
Enrollment StartNov 2021
Primary CompletionNov 2023
TodayJul 2026
Study CompletionJan 2027
First PostedOct 22, 2021
Enrollment StartNov 17, 2021
Primary CompletionNov 29, 2023
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.7 years ago
Interventions
Sacituzumab Govitecan-hziy (SG)biological
Administered intravenously
Docetaxeldrug
Administered intravenously